<DOC>
	<DOCNO>NCT00162149</DOCNO>
	<brief_summary>Open-Label , multiple-dose , drug interaction study assess effect nevirapine pharmacokinetics atazanavir HIV-infected individual .</brief_summary>
	<brief_title>ATV/Ritonavir Nevirapine Interaction ( USPAC )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>sign informed consent form For Cohort 1 , HIVinfected subject receive nevirapine 200 mg twicedaily 2 3 NRTIs least 6 week For Cohort 2 , HIVinfected subject receive atazanavir 300 mg ritonavir 100 mg oncedaily 2 3 NRTIs least 6 week Have 2 measurement plasma HIV RNA &lt; 400 copies/mL . The first test 6 16 week prior second within 3 week prior Day 1 Have CD4 cell count &gt; =200 cells/mm3 Body Mass Index 18 35 kg/m2 . Men woman , age 18 55 . Women pregnant breastfeed Presence newly diagnose HIVrelated opportunistic infection CD4 cell count &lt; 200 cell/mm3 within previous 6 month . Any significant acute chronic medical illness , unless stable control nonprohibited medication . History virologic failure antiretroviral regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>